Small-molecule inhibitors targeting viral proteins could serve as an effective alternative for controlling the spread of COVID-19 at both individual and community levels. In this vein, a recent study ...

The COVID-19 pandemic highlighted the urgent need for effective therapeutic agents against SARS-CoV-2. Although vaccines ...

“This is how viruses evolve. It is not surprising that SARS-CoV2 has become very weak now. It would probably still not be ...

Back in 2021, at the height of the pandemic, scientists at Pfizer revealed the development of a novel antiviral molecule, ...

CoV-2 nucleocapsid antibodies to detect exposure to SARS-CoV-2: results from a prospective cohort study on COVID-19 ...

A slow immune response to SARS-CoV-2 infection, delayed viral clearance, and viral rebound can all increase a person’s risk ...

Researchers from the Institute of Science Tokyo have developed CeSPIACE, a peptide inhibitor that blocks SARS-CoV-2 from ...

The current number of long COVID-19 cases may already be costing the U.S. $2.01–6.56 billion dollars per year, according to a ...

Although several vaccines and drugs are available against SARS-CoV-2, the search for effective therapeutic agents for COVID-19 and future zoonotic coronaviruses continues. The RNA-dependent RNA ...

Today in BMC Medicine, researchers in Catalonia, Spain, estimate that 23% of adult COVID-19 survivors develop long COVID, ...

SARS secures R7. 5 billion investment to revolutionise tax collection through AI and machine learning, while Commissioner ...